MicroRNA profiling in the left atrium in patients with non-valvular paroxysmal atrial fibrillation by Wang, Jiangang et al.
RESEARCH ARTICLE Open Access
MicroRNA profiling in the left atrium in patients
with non-valvular paroxysmal atrial fibrillation
Jiangang Wang1*, Shiqiu Song1, Changqing Xie2, Jie Han1, Yan Li1, Jiahai Shi3, Meng Xin1, Jun Wang1, Tiange Luo1,
Xu Meng1 and Bo Yang4
Abstract
Background: We aimed to identify the miRNA expression profiles in left atrial appendage, with the intention of
identifying miRNAs that were significantly associated with non-valvular paroxysmal AF.
Methods: The RNA samples were isolated from healthy controls (n = 5) and patients with atrial fibrillation (n = 8). To
confirm the findings obtained by analyzing the miRNA profile, we measured the expression of selected miRNAs in
the entire cohort by quantitative PCR.
Results: Ten specific miRNAs were found to be differentially expressed between atrial fibrillation and healthy controls
with more than a 2-fold change (P < 0.05). Consistent with the data obtained for the profile, expression levels of
miRNA-155, miRNA-146b-5p and miRNA-19b were significantly increased in patients with atrial fibrillation. Interestingly,
levels of miRNA-146b-5p and miRNA-155, which are known to be associated with inflammation, were independently
and positively associated with left atrium dimension, atrial fibrillation duration and high sensitivity C-reactive protein
levels. By using four Databases (TargetScan, miRanda, Starbase Clip-seq and miRDB) to perform target gene prediction,
there were four genes were related to the inflammatory response and fibrosis, and three others encoding cardiac ion
channel proteins. As a result of TaqMan qPCR and Western analysis, the relative mRNA and protein expression level of
three target genes (DIER-1, TIMP-4 and CACNA1C) were significantly lower in the atrial fibrillation group than that in
the healthy control group.
Conclusions: Expression of inflammation-associated miRNAs is significantly up-regulated in the left atrial appendage of
patients with non-valvular paroxysmal atrial fibrillation, which may play a significant role in electrical and structural
remodeling.
Background
MiRNAs are endogenous ~23 nt RNAs that play important
gene-regulating roles in animals and plants by pairing to
the messenger RNAs (mRNAs) of protein-coding genes to
direct their post-transcriptional regulation [1, 2]. Therefore,
measuring miRNA expression can be useful for gene regu-
lation studies at systems-level, especially when miRNA
measurements are combined with mRNA profiling and
other genome-scale data. Also, it is reported that miRNAs
are unusually well-preserved in a range of biological speci-
mens. This has led to considerable interest in the develop-
ment of miRNAs as biomarkers for diverse molecular
diagnostic applications, including in the treatment of
cancer, cardiovascular diseases, autoimmune diseases and
forensics [3–5]. Accordingly, miRNA profiling has become
an area of interest for researchers and investigators working
in various areas of biology and medicine [6].
Atrial fibrillation (AF) is the most common sustained
cardiac rhythm disorder, and is increasing in prevalence
and incidence [7, 8]. With the recent and rapid strides in
the field of miRNA research, investigators have begun to
appreciate the roles of mRNAs in the cardiovascular sys-
tem [9]. Several studies have reported the direct involve-
ment of miRNAs in controlling the cardiac excitability
and arrhythmogenesis in specific pathophysiological
conditions [10–12]. A group of miRNAs (such as miR-1
and miR-328) have been shown to regulate the genes
encoding cardiac ion channel proteins and other relevant
genes. Some of these miRNAs have been shown to be
involved in AF, and some are considered to have the
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potential to regulate AF based on their target genes
[13–15]. However, since most of the specimens have been
obtained from patients with valvular AF, from previous
studies one cannot distinguish whether the findings reveal
inherent characteristics of the atria themselves or are due
to underlying valvular heart diseases.
AF is as a complex electrical phenotype involving
complex factors beyond electrophysiology. AF may have
distinct underlying mechanisms, and different miRNAs
might be involved in different types of AF. Currently, there
is a growing body of evidence suggesting that a specifically
altered pattern of miRNA expression in atrial tissue and
plasma is associated with AF [16–20]. However, the miRNA
signature in AF, particularly in non-valvular AF, is still
unknown. Here we aimed to identify the miRNA expres-
sion profiles in left atrial appendage (LAA), with the
intention of identifying miRNAs that were significantly
associated with non-valvular paroxysmal AF (PAF).
Methods




A total of 47 subjects were studied. LAAs were obtained
from 30 patients with PAF. The mean age was 48.5 ±
7.2 years, and 63 % were males. The time since the first
diagnosis of AF was ≈ 2 years. The mean left atrial diam-
eter (LAD) was 53.1 ± 2.2 mm. The HC group consisted
of seventeen dumped LAA samples obtained from trans-
plant donors following heart transplantation. The HC
group consisted of 13 males and 4 females; their mean
age was 33 ± 1.3 years. The clinical characteristics of the
2 study populations are summarized in Additional file 2.
MiRNA profiles in AF patients versus healthy controls
To determine the levels of miRNAs in LAA in patients with
non-valvular PAF, we performed miRNA profiling in 8
patients with AF and in 5 HCs (Additional file 3 and Add-
itional file 4). The miRNA expression profiles of AF and
HCs were compared. The levels of miRNAs profoundly dif-
fered between patients and HCs, as illustrated in the heat
map diagram shown in Fig. 1a. Quantification revealed that
10 miRNAs were differentially expressed between the pa-
tients and HCs with more than 2-fold change (P < 0.05).
These miRNAs were miR-155, miR-146b-5p, miR-19b,
miR-142-3p, miR-486-5p, miR-223, miR-193b, miR-519b-
3p, miR-301b and miR-193a-5p.
The RT-PCR analysis confirmed the significant up-
regulation of miR-155, miR-146b-5p, miR-19b, miR-142-
3p, miR-486-5p, miR-223, miR-193b, miR-519b-3p and
miR-301b, and significant down-regulation of miR-193a-
5p (Fig. 1b). In particular, miR-155, miR-146b-5p, and
miR-19b demonstrated the most pronounced changes
among the 10 differentially expressed miRNAs. These
qRT-PCR results confirmed the miRNA microarray
results and indicated the potential roles of miRNAs in
the progression of AF.
To confirm the findings of the miRNA profile analysis,
we measured the expression of selected miRNAs in the
entire cohort (n = 47) by using TaqMan quantitative
PCR (qPCR). As shown in Fig. 2, the expression of
predominantly inflammation-associated miRNAs such as
miR-146b-5p, miR-19b, and miR-155 [21–23] were
significantly increased in patients with AF.
Fig. 1 Profile of miRNAs in patients with atrial fibrillation versus health controls. a Heat map diagram t. b qRT-PCR verification of the miRNA expression
profile in atrial fibrillation. ***P < 0.001; **P < 0.01; *P < 0.05
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Correlation between miRNAs expression and AF
To determine the factors that influence the levels of
miRNAs, we analyzed the association between miRNAs
and the baseline characteristics of the patients. There were
significant positive correlations between the expression of
miR-146b-5p and miR-155, and AF patients’ LAD, plasma
levels of high sensitivity C-reactive protein (hsCRP) and
AF duration, respectively (Fig. 3). Interestingly, the LAD,
AF duration and hsCRP levels are considered to be predic-
tors of increased risk for the AF recurrence [24, 25].
To verify whether the up-regulation of these in-
flammation-associated miRNAs is the main factor for re-
currence of AF, we analyzed the expression of miRNAs in
patients with sinus rhythm (SR group) and in patients
who had recurrence of AF (AF group) in our original
cohort after 2 year follow-up (Additional file 5). As shown
in the table, the miRNA-155 and miR-146b expression
levels, LAD, hsCRP levels, and AF duration were found to
significantly predict recurrence in the univariate regres-
sion models. However, in multivariate analysis only
miRNA-155 [Hazard Ratio [HR], 1.113; P = 0.037) and
miR-146b-5p (HR, 1.646; P = 0.030) expression levels,
LAD (HR, 1.036; P = 0.039) and AF duration (HR, 1.216;
P = 0.044) were found to significantly predict the recur-
rence of AF.
MiRNAs expression profile is correlated with genes that
are involved in AF
Given the fact that miRNA is involved in post-tran-
scriptional regulation, we endeavored to determine
whether there is was correlation between the levels of
miRNAs expression and their target genes involved in the
pathogenesis of AF. We performed target prediction for
miRNAs by using 4 Databases (TargetScan, miRanda, Star-
base Clip-seq and miRDB) and identified the genes, based
on the similar prediction by at least the 3 of the 4
databases. We found that at least 7 genes were related to
AF. Among these, 4 genes were related to the inflammatory
response and fibrosis, and three others encoding cardiac
ion channel proteins (Additional file 6).
Fig. 3 Correlation between expression levels of miRNA-155, miRNA-146b-5p and left atrium dimension, atrial fibrillation duration and high
sensitivity C-reactive protein
Fig. 2 Validation of the differentially expressed miRNAs by qRT-PCR. Expression of selected miRNAs in left atrial antrum obtained from patients
with atrial fibrillation (n = 30) and health controls (n = 17), as determined by TaqMan PCR. *** P < 0.001; ** P < 0.01; * P < 0.05
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MRNA and protein expression of target gene
To determine whether those seven predicted target genes
were involved in non-valvular PAF, we measured those
expression of mRNA and protein in the entire cohort
(n = 47). As a result of TaqMan qPCR, the relative mRNA
expression level of the DIER-1, TIMP-4 and CACNA1C
were significantly lower in the AF group than that in the
HC group (Fig. 4a). As a result of Western blotting
analysis, the DIER-1, TIMP-4 and CACNA1C protein
expression were also significantly lower in AF group than
in HC group (Fig. 4b).
Discussion
The most important results of our study may be summa-
rized as follows: 1. Expression levels of miR-155, miR-146b-
5p and miR-19b were significantly increased in patients
with non-valvular PAF compared with HCs. 2. Levels of
miR-146b-5p and miR-155, which are known to be associ-
ated with inflammation, were independently and positively
associated with LAD, AF duration and hsCRP levels. 3. On
multivariate analysis only miR-155 and miR-146b-5p
expression levels, LAD, and AF duration were found to
significantly predict AF recurrence after procedure.
Co-morbidities might affect miRNAs expression
This study provides the first profiling of miRNAs in
patients with non-vavular PAF and HCs. We found that in
the LAA miR-155, miR-146b-5p and miR-19b are aber-
rantly up-regulated in patients with AF compared with
HCs. A group of miRNAs regulate genes encoding cardiac
ion channel proteins and other relevant genes, and several
studies have reported the direct involvement of miRNAs in
controlling cardiac excitability and arrhythmogenesis in
certain pathological conditions [12]. Some such miRNAs
have been shown to be directly involved in AF, and some
are considered to have the potential to regulate AF based
on their target genes. However, to our knowledge, earlier
investigations verified the regulation of miRNAs in the
atrial tissue from patients with valvular AF and other co-
morbidities in non-AF patients (such as coronary heart
disease). Therefore, from those studies it would not possible
Fig. 4 Expression level of target genes in the atrial fibrillation (AF) group (n = 30) and healthy control (HC) group (n = 17). a The relative mRNA
expression level of the target genes as determined by TaqMan PCR. b Protein expression of the target genes using the Western blot. ***P < 0.001;
**P < 0.01; *P < 0.05
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to deduce whether pre-existing heart diseases already influ-
enced the expression of miRNAs.
Previous studies have reported that expression of miR-
NAs such as miR-1, miR-328 and miR-499 are altered in
valvular AF patients, but it did not significantly change
in our study [13–15]. This variation in the findings,
compared with other studies, may be attributed to the
differences in the tissues that were sampled (LAA in the
current study versus left atrial tissue in the other previ-
ous studies) and the heterogeneity of human myocardial
samples. AF is a multifaceted electrical phenotype
involving complex factors beyond electrophysiology and
can occur in a variety of pathological settings. The differ-
ent types of AF have distinct underlying mechanisms,
and different miRNAs might be involved. The results of
Cooley and Xiao et al. showed that the presence of
valvular heart disease in AF influenced miRNA expres-
sion patterns in both left and right atria [16, 17].
Morphological and electrophysiological differences have
been demonstrated between theright atria and left atria,
which at least in part, may reflect different mecha-
nisms involved in AF between the right atria and left
atria. Thus, it is not surprising that AF-associated
miRNAs of the right atria may differ from those of the
left atria. A recent study compared the potential dif-
ferences of AF-associated miRNAs in the RA and LA
from rheumatic mitral valve disease patients. They
have found the different distributions of AF-associated
miRNAs in the right atrial appendage and LAA from
rheumatic mitral valve disease patients. This may re-
flect different miRNA mechanisms in AF between the
RA and LA. 26 But for the non-valvular AF, AF substrate in
the left atria is related to AF initiation and maintenance,
which plays an important role to initiate and perpetuate
AF. And the potential difference of AF-associated miRNAs
between right atria and left atria are still unknown due to
lack of the RA and LA sample availability.
In our study miR-155, miR-146b-5p, and miR-19b
were significantly up-regulated in non-valvular PAF
patients. Most important, we also found significantly
higher levels of expression of miR-155 and miR-146b-5p
were independently associated with LAD, AF duration
and hsCRP levels. However, only miR-155 and miR-146b
expression level, LA dimension and AF duration were
found to significantly predict AF recurrence in multi-
variate analysis.
Role of LAA in maintaining AF
Less invasive AF ablation procedures have been devel-
oped due to increasing knowledge about the pathophysi-
ology of AF and due to the development of ablation
devices, which replace the original ‘cut-and-sew’ tech-
nique for scarification [26, 27]. Wolf et al. developed an
off-pump procedure, in which the pulmonary veins
(PVs) are isolated, ganglionic plexus are ablated, and the
LAA is amputated through a bilateral thoracotomy [26].
The LAA is derived from the primordial left atrium,
which is formed mainly by the adsorption of the primor-
dial PVs and their branches. This similar embryological
origin suggests that the LAA may initiate AF like the
PVs. This could explain the potential and active role of
LAA as an underestimated source of AF. In our study,
miRNAs profiling in LAA provided very compelling
evidence, which illustrated the potential of miRNAs as a
new mechanism for non-valvular PAF.
MiRNAs and cardiac remodeling
Interestingly, miR-155, which is reported to be involved
in cardiovascular diseases, showed the largest increases
in our AF patients compared with HCs. miR-155 might
directly influence arrhythmia outcomes by targeting crit-
ical ion channel gene expression, including CACNA1C
and KCNA4, which encode the cardiac L-type Ca2+
channel (ICaL) α1c and the initial component of the tran-
sient outward potassium current (Ito1), respectively. And
our results showed that the expression of the CACNA1C
was significantly lower in the AF group than the HC
group, not only for the protein level, but also the mRNA
level. Moreover, miR-155 up-regulation may also play a
role in inflammation [21]. In fact, emphasis has been
given to miR-155 because it represents a typical multi-
functional miRNA [28]. Even though the mechanism
that regulates miRNA function and expression has not
been completely understood, the information presently
available (i.e. over expression in AF patients) allows us
to recognize miR-155 as a gene of potentially paramount
clinical importance in AF diagnosis and treatment. It is
reasonable to speculate that evaluation of mRNA-155 in
tissues or biological fluids might be utilized as a bio-
chemical parameter for AF detection and prognosis.
MiR-146, is also thought to be a mediator of inflam-
mation along with miR-155 [29]. The expression of miR-
146 is up-regulated by inflammatory factors such as
interleukin 1 and tumor necrosis factor [22]. miR-146
regulates a number of targets, which are mostly involved
in Toll-like receptor pathways that bring about a cyto-
kine response as part of the innate immune system [30].
Recently, miR-146b-5p was reported to be up-regulated
in AF patients, which is consistent with our findings
[18]. Potential targets of miR-146b-5p include TGIF1,
MMP16 and TIMP4 that are reported to be regulated in
cardiomyocyte fibrosis, and these might be expected to
contribute to AF by promoting fibrosis, an established
AF substrate [31]. This possibility remains to be investi-
gated. Our results showed that the expression of the
TIMP-4 was significantly lower in the LAA of the AF
group than in that of the HC group, not only for the
protein level, but also the mRNA level.
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MiR-19b also takes part in inflammatory responses
enhancing or repressing pro-inflammatory mediators’
expression [23]. It positively regulates Toll-like receptor
signaling with DICER-1 deletion and miRNA depletion.
The miR-19b is an important protagonist in this
phenomenon, regulating positively the NF-kB activity
[23]. The miRNA depletion inhibits cytokines produc-
tion by NF-kB. Also, it is directly involved in the modu-
lation of several NF-kB signaling negative regulators
expression, indicating the importance of miR-19b on
NF-kB signaling. This miRNA has not been extensively
studied, but our data suggests a possible role of this
miRNA in the pathology of AF, which is yet to be
identified.
Study limitations
One of the limitations of the present study is that at this
point we are unable to provide molecular insights for
the cause of miRNA dysregulation in non-valvular PAF.
The levels of miRNAs may be affected by multiple
factors such as the change in expression in the tissue,
the release of the miRNAs by the cells and the stability
of miRNAs. Secondly, the exact targets and pathways by
which alterations in miRNAs cause AF remain elusive.
Although our analysis has indicated some potential
genes and pathways that are involved in AF, it is difficult
to estimate the actual false-positive rate of the overall
target prediction. A better understanding of the bio-
logical significance of these broad, but often subtle,
changes in miRNA expression that are found in AF
patients could be achieved with the development of
novel experimental models, in which the levels of one or
more miRNAs could be precisely manipulated.
Conclusions
The present study provides the first insight into the levels
of miRNAs in the LAA in patients with non-valvular PAF.
While previous studies have demonstrated reliable meas-
urement of miRNAs, our study specifically addressed the
levels and regulation of ionic, inflammatory and fibrotic de-
rived miRNAs and shows, specific miRNAs which may be
involved in both electrical and structural remodeling of the
fibrillating atria. However, these data further need to be
confirmed in larger clinical population. Furthermore, the
mechanisms underlying the dysregulation, and as well as
the putative impact of the changes in miRNAs levels in the
physiology or pathophysiology, remains to be elucidated.
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